Jason Hill

Title: Jason Hill: Innovator in ErbB Ligand Binding Molecules

Introduction

Jason Hill is a prominent inventor based in Chicago, IL (US). He has made significant contributions to the field of molecular biology, particularly in the development of ErbB ligand binding molecules. With a total of 3 patents, his work has the potential to impact the treatment of various diseases.

Latest Patents

One of Jason Hill's latest patents focuses on broad spectrum ErbB ligand binding molecules and methods for preparing and using them. These chimeric ErbB ligand binding molecules exhibit detectable binding activity for a wider range of ErbB ligands than any one of the native ErbB receptors, including ErbB1, ErbB3, or ErbB4. The binding molecules are designed to bind a broad spectrum, ideally the full spectrum of ErbB ligands. The chimeric molecules typically consist of a subunit LI derived from one of the ErbB receptors and a subunit LII derived from a different ErbB receptor type. The sub-domain SI, which connects LI and LII, can originate from either receptor type or include portions from both. Additionally, pharmaceutical compositions containing these molecules and methods for treating ErbB-sensitive diseases are also disclosed in his patents.

Career Highlights

Throughout his career, Jason Hill has worked with various companies, including Ligacept LLC and Targeted Molecular Diagnostics. His experience in these organizations has contributed to his expertise in the field of molecular diagnostics and therapeutic development.

Collaborations

Jason has collaborated with notable professionals, including Sarah S Bacus, enhancing the scope and impact of his research.

Conclusion

Jason Hill's innovative work in the development of ErbB ligand binding molecules showcases his dedication to advancing medical science. His contributions have the potential to lead to significant advancements in the treatment of ErbB-sensitive diseases.